Cargando…

Correction to: Rilonacept (Interleukin‑1 Inhibition) for the Treatment of Pericarditis

Detalles Bibliográficos
Autores principales:	Wang, Tom Kai Ming, Klein, Allan L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895100/ https://www.ncbi.nlm.nih.gov/pubmed/35080705 http://dx.doi.org/10.1007/s11886-022-01648-x

Ejemplares similares

Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis
por: Wang, Tom Kai Ming, et al.
Publicado: (2022)

Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis
por: Brucato, Antonio, et al.
Publicado: (2023)

Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial
por: Klein, Allan L, et al.
Publicado: (2021)

Rilonacept and Anakinra in Recurrent Pericarditis: A Systematic Review and Meta-Analysis
por: Affas, Ziad R, et al.
Publicado: (2022)

SARS-COV-2 AND MRNA VACCINE-ASSOCIATED RECURRENT PERICARDITIS TREATED WITH RILONACEPT
por: Shell, John Clark, et al.
Publicado: (2023)

Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY
por: Brucato, Antonio, et al.
Publicado: (2022)

Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept
por: Lin, David, et al.
Publicado: (2021)

Inhibition of interleukin‐1 with rilonacept is not effective in cold urticaria—Results of a randomized, placebo‐controlled study
por: Bonnekoh, Hanna, et al.
Publicado: (2023)

Emerging Therapies for Recurrent Pericarditis: Interleukin‐1 inhibitors
por: Lo Presti, Saberio, et al.
Publicado: (2021)

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
por: Gillespie, Justin, et al.
Publicado: (2010)

Anti-interleukin-1 agents for pericarditis: a primer for cardiologists( )
por: Imazio, Massimo, et al.
Publicado: (2021)

Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis
por: Abadie, Bryan Q., et al.
Publicado: (2022)

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study
por: Terkeltaub, R, et al.
Publicado: (2009)

Correction to: Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome
por: Lutschinger, Leon L., et al.
Publicado: (2019)

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator
por: Terkeltaub, Robert A, et al.
Publicado: (2013)

Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
por: Church, Leigh D, et al.
Publicado: (2008)

Correction to: A rare case of pericarditis and pleural empyema secondary to transdiaphragmatic extension of pyogenic liver abscess
por: Cho, Eunae, et al.
Publicado: (2020)

Rilonacept (IL-1 TRAP) for treatment of colchicine resistant familial mediterranean fever (FMF): a randomized, multicenter double-blinded, alternating treatment trial
por: Hashkes, PJ, et al.
Publicado: (2011)

The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges
por: Lazaros, George, et al.
Publicado: (2017)

Correction to: microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11
por: Cai, Wei-Luo, et al.
Publicado: (2020)

Correction: Mahasing et al. Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand. Vaccines 2023, 11, 749
por: Mahasing, Chayanit, et al.
Publicado: (2023)

Correction: Colon cancer-induced interleukin-35 inhibits betacatenin- mediated pro-oncogenic activity
por: Jiang, Yueqiang, et al.
Publicado: (2018)

The Effect of Rilonacept versus Placebo on Health-Related Quality of Life in Patients with Poorly Controlled Familial Mediterranean Fever
por: Hashkes, Philip J., et al.
Publicado: (2014)

Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children
por: Signa, Sara, et al.
Publicado: (2020)

Correction: Interleukin-6: a new therapeutic target
por: Smolen, Josef S, et al.
Publicado: (2006)

Correction: Historical overview of the interleukin-6 family cytokine
por: Kang, Sujin, et al.
Publicado: (2020)

The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review
por: Baskar, Shankar, et al.
Publicado: (2016)

Correction: Inhibition of IGF-1R Prevents Ionizing Radiation-Induced Primary Endothelial Cell Senescence
por: Panganiban, Ronald Allan M., et al.
Publicado: (2014)

Correction to “Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells”
por: Li, Chuan-Hong, et al.
Publicado: (2023)

Correction: Chae, H.S.; et al. Atractylodin Inhibits Interleukin-6 by Blocking NPM-ALK Activation and MAPKs in HMC-1. Molecules 2016, 21, 1169
por: Chae, Hee-Sung, et al.
Publicado: (2016)

A Malignant Case of Constrictive Pericarditis
por: Betancor, Jorge, et al.
Publicado: (2017)

An Unusual Case of Parasitic Constrictive Pericarditis
por: Agrawal, Ankit, et al.
Publicado: (2023)

Correction to: Mutant glucocorticoid receptor binding elements on the interleukin-6 promoter regulate dexamethasone effects
por: Chang, Wen-Teng, et al.
Publicado: (2021)

Correction: Increased Interleukin-17 in Peripheral Blood and Cerebrospinal Fluid of Neurosyphilis Patients
por: Wang, Cuini, et al.
Publicado: (2015)

Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
por: Váraljai, Renáta, et al.
Publicado: (2023)

Correction: Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature
Publicado: (2022)

Correction: Interleukin-17 receptor C gene polymorphism reduces treatment effect and promotes poor prognosis of ischemic stroke
Publicado: (2020)

Correction: Ping Meng, et al. Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses. Int. J. Mol. Sci. 2016, 17, 1070
por: Meng, Ping, et al.
Publicado: (2016)

The Treatment of Pericarditis with Effusion
Publicado: (1899)

Correction: Interleukin-1 Receptor Antagonist Has a Novel Function in the Regulation of Matrix Metalloproteinase-13 Expression
por: Goto, Hisashi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jr9j879pllgbqneb26r521l37g